Benefits of prolonged-release pirfenidone plus standard of care treatment in patients with advanced liver fibrosis: PROMETEO study

Portal pressure and liver stiffness measurements in the prediction of fibrosis regression after sustained virological response in recurrent hepatitis C

(2018) Ezequiel Mauro et al.   HEPATOLOGY

Usefulness of biochemical remission and transient elastography in monitoring disease course in autoimmune hepatitis

(2018) Johannes Hartl et al.   JOURNAL OF HEPATOLOGY

Progress in non-invasive detection of liver fibrosis

(2018) Li Chengxi et al.   Cancer Biology & Medicine

Serum cytokines, adipokines and ferritin for non-invasive assessment of liver fibrosis in chronic liver disease: a systematic review

(2018) Seyyed Mortaza Haghgoo et al.   CLINICAL CHEMISTRY AND LABORATORY MEDICINE

Relationship Between Three Commonly Used Non-invasive Fibrosis Biomarkers and Improvement in Fibrosis Stage in Patients With NASH

(2018) Naga Chalasani et al.   LIVER INTERNATIONAL

Antifibrotics in liver disease: are we getting closer to clinical use?

(2018) Meena B. Bansal et al.   Hepatology International

American Gastroenterological Association Institute Guideline on the Role of Elastography in the Evaluation of Liver Fibrosis

(2017) Joseph K. Lim et al.   GASTROENTEROLOGY

Immune dysfunction in cirrhosis: Distinct cytokines phenotypes according to cirrhosis severity

(2016) Melisa Dirchwolf et al.   CYTOKINE

A Journal of Biomedical Science: Of Its Practitioners, by Its Practitioners, and for Its Practitioners

(2016)   FASEB JOURNAL

TGF-β: the master regulator of fibrosis

(2016) Xiao-ming Meng et al.   Nature Reviews Nephrology

Fibrogenic Polymorphisms (TGF-β, PAI-1, AT) in Mexican Patients With Established Liver Fibrosis. Potential Correlation With Pirfenidone Treatment

(2016) Juan Armendáriz-Borunda et al.   JOURNAL OF INVESTIGATIVE MEDICINE

Role and New Insights of Pirfenidone in Fibrotic Diseases

(2015) David Alejandro Lopez-de la Mora et al.   International Journal of Medical Sciences

Treatment with pirfenidone for two years decreases fibrosis, cytokine levels and enhances CB2 gene expression in patients with chronic hepatitis C

(2014) Lucia Flores-Contreras et al.   BMC GASTROENTEROLOGY

Non-invasive assessment of liver fibrosis with impulse elastography: Comparison of Supersonic Shear Imaging with ARFI and FibroScan®

(2014) Christophe Cassinotto et al.   JOURNAL OF HEPATOLOGY

Pirfenidone for the treatment of idiopathic pulmonary fibrosis

(2013) Antoni Xaubet et al.   EXPERT OPINION ON PHARMACOTHERAPY

Staging chronic hepatitis C in seven categories using fibrosis biomarker (FibroTest™) and transient elastography (FibroScan®)

(2013) Thierry Poynard et al.   JOURNAL OF HEPATOLOGY

NICE guidance on pirfenidone for treating idiopathic pulmonary fibrosis

(2013) Linda J Landells et al.   Lancet Respiratory Medicine

Clinical evidence for the regression of liver fibrosis

(2012) Elizabeth L. Ellis et al.   JOURNAL OF HEPATOLOGY

Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study

(2012) Patrick Marcellin et al.   LANCET

Alcohol-related cirrhosis-early abstinence is a key factor in prognosis, even in the most severe cases

(2009) Clare Verrill et al.   ADDICTION

Effect of food and antacids on the pharmacokinetics of pirfenidone in older healthy adults

(2009) C.M. Rubino et al.   PULMONARY PHARMACOLOGY & THERAPEUTICS

Effective use of FibroTest to generate decision trees in hepatitis C

(2009) Dana Lau-Corona et al.   WORLD JOURNAL OF GASTROENTEROLOGY